on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics' new strategic plan for 2026-2028
On December 9, 2025, OSE Immunotherapeutics presented an ambitious strategic plan for the period 2026-2028. The company is focusing on four key areas to maximize value creation. First, the completion of the Phase 3 trial of Tedopi® in non-small cell lung cancer is planned, with analyses expected in 2026 and 2028. This project will require limited financial investment. Second, Lusvertikimab is slated for development for rare diseases, leveraging its intravenous formulation.
The company also plans to develop a subcutaneous version of Lusvertikimab for ulcerative colitis. Finally, OSE Immunotherapeutics intends to strengthen its scientific leadership through innovation and rigorous management of its intellectual property. A balanced financial strategy aims to limit shareholder dilution while securing diversified funding. A webinar is scheduled for December 10 to detail this plan to stakeholders.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news